ASTHMA AND COPD MARKET ANALYSIS

Market News

Global Asthma And COPD Market: Key Developments

 In February 2020, Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd, a China-based biopharmaceutical company, approved to start clinical trial of new Anti-IL-5 monoclonal antibody drug for treatment of asthma in China.

In June 2020, Novartis Pharma K.K, the Japan business of strategic alliance partner Novartis AG, a Switzerland-based multinational pharmaceutical comapany, announced the manufacturing and marketing approval for its Enerzair Inhalation Capsules (medium-dose and high-dose) in Japan as a treatment of bronchial asthma.

In August 2022, Upstream Bio, a U.S.-based drug developer, initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.

On 9 February 2022, Generium, a Russia-based pharmaceutical company, announced the launch of Omalizumab in Russia, under the brand name Genolar. Genolar is a recombinant humanized IgG1k monoclonal antibody that binds to free human immunoglobulin E (IgE). The product is available in Russia for the treatment of persistent atopic bronchial asthma (the most common form of asthma) in patients aged 6 and older.